Story perspectives

GSK to Acquire RAPT Therapeutics for $2.2 Billion

1/20/2026

Summary

Story summary

GSK will acquire RAPT Therapeutics for $2.2 billion, paying $58 per share, a 65% premium over RAPT's recent closing price.
The acquisition includes ozureprubart, a monoclonal antibody in phase IIb trials for food allergies, which offers less frequent dosing every 12 weeks.
This deal allows GSK to enhance its portfolio in respiratory and immunology sectors, addressing the needs of over 17 million people in the U.S. with food allergies.
The acquisition is expected to close in the first quarter of 2026.

1 of 1

Story summary

GSK will acquire RAPT Therapeutics for $2.2 billion, paying $58 per share, a 65% premium over RAPT's recent closing price.
The acquisition includes ozureprubart, a monoclonal antibody in phase IIb trials for food allergies, which offers less frequent dosing every 12 weeks.
This deal allows GSK to enhance its portfolio in respiratory and immunology sectors, addressing the needs of over 17 million people in the U.S. with food allergies.
The acquisition is expected to close in the first quarter of 2026.